JP2019525897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019525897A5 JP2019525897A5 JP2018563925A JP2018563925A JP2019525897A5 JP 2019525897 A5 JP2019525897 A5 JP 2019525897A5 JP 2018563925 A JP2018563925 A JP 2018563925A JP 2018563925 A JP2018563925 A JP 2018563925A JP 2019525897 A5 JP2019525897 A5 JP 2019525897A5
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- residue
- amino acid
- item
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims description 190
- 102000018358 immunoglobulin Human genes 0.000 claims description 190
- 239000000427 antigen Substances 0.000 claims description 123
- 102000036639 antigens Human genes 0.000 claims description 123
- 108091007433 antigens Proteins 0.000 claims description 123
- 125000000539 amino acid group Chemical group 0.000 claims description 120
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 120
- 238000000034 method Methods 0.000 claims description 72
- 125000002252 acyl group Chemical group 0.000 claims description 55
- 239000000758 substrate Substances 0.000 claims description 55
- 239000003795 chemical substances by application Substances 0.000 claims description 52
- 230000037431 insertion Effects 0.000 claims description 42
- 238000003780 insertion Methods 0.000 claims description 42
- 230000002378 acidificating effect Effects 0.000 claims description 37
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 32
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 24
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 24
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 23
- 239000004473 Threonine Substances 0.000 claims description 23
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 23
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 21
- 229940024606 amino acid Drugs 0.000 claims description 18
- 235000001014 amino acid Nutrition 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 14
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 13
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 13
- 108060008539 Transglutaminase Proteins 0.000 claims description 13
- 235000009582 asparagine Nutrition 0.000 claims description 13
- 229960001230 asparagine Drugs 0.000 claims description 13
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 13
- 230000000813 microbial effect Effects 0.000 claims description 13
- 102000003601 transglutaminase Human genes 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 12
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 11
- 239000000032 diagnostic agent Substances 0.000 claims description 11
- 229940039227 diagnostic agent Drugs 0.000 claims description 11
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 9
- 229930182817 methionine Natural products 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- 235000003704 aspartic acid Nutrition 0.000 claims description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 7
- 235000013922 glutamic acid Nutrition 0.000 claims description 7
- 239000004220 glutamic acid Substances 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- -1 carboxylbenzyloxy (CBZ) group Chemical group 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 125000003827 glycol group Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 230000001268 conjugating effect Effects 0.000 claims description 3
- 239000002254 cytotoxic agent Substances 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 22
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 12
- 235000018417 cysteine Nutrition 0.000 description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 description 6
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 6
- 229960000310 isoleucine Drugs 0.000 description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- 239000004474 valine Substances 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- URYYVOIYTNXXBN-OWOJBTEDSA-N trans-cyclooctene Chemical compound C1CCC\C=C\CC1 URYYVOIYTNXXBN-OWOJBTEDSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- LGNCNVVZCUVPOT-FUVGGWJZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical group CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LGNCNVVZCUVPOT-FUVGGWJZSA-N 0.000 description 2
- QRZUPJILJVGUFF-UHFFFAOYSA-N 2,8-dibenzylcyclooctan-1-one Chemical compound C1CCCCC(CC=2C=CC=CC=2)C(=O)C1CC1=CC=CC=C1 QRZUPJILJVGUFF-UHFFFAOYSA-N 0.000 description 2
- ZUHQCDZJPTXVCU-UHFFFAOYSA-N C1#CCCC2=CC=CC=C2C2=CC=CC=C21 Chemical compound C1#CCCC2=CC=CC=C2C2=CC=CC=C21 ZUHQCDZJPTXVCU-UHFFFAOYSA-N 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- NSVXZMGWYBICRW-ULKQDVFKSA-N [(1s,8r)-9-bicyclo[6.1.0]non-4-ynyl]methanol Chemical group C1CC#CCC[C@@H]2C(CO)[C@@H]21 NSVXZMGWYBICRW-ULKQDVFKSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 2
- 241001495137 Streptomyces mobaraensis Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348410P | 2016-06-10 | 2016-06-10 | |
| US62/348,410 | 2016-06-10 | ||
| PCT/JP2017/021672 WO2017213267A1 (en) | 2016-06-10 | 2017-06-12 | Lysine conjugated immunoglobulins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019525897A JP2019525897A (ja) | 2019-09-12 |
| JP2019525897A5 true JP2019525897A5 (cg-RX-API-DMAC7.html) | 2020-07-16 |
| JP7041077B2 JP7041077B2 (ja) | 2022-03-23 |
Family
ID=59315675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563925A Active JP7041077B2 (ja) | 2016-06-10 | 2017-06-12 | リジン結合体化免疫グロブリン |
Country Status (21)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2747581C2 (ru) | 2015-12-18 | 2021-05-11 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Конъюгированные иммуноглобулины с c-концевым лизином |
| SG11201810470XA (en) | 2016-06-10 | 2018-12-28 | Eisai R&D Man Co Ltd | Lysine conjugated immunoglobulins |
| CN114702587A (zh) * | 2019-05-09 | 2022-07-05 | 美勒斯公司 | 用于使蛋白质多聚化的变体结构域及其分离 |
| GB201907093D0 (en) * | 2019-05-20 | 2019-07-03 | Ucl Business Plc | Antibody functionalisation |
| JP7664943B2 (ja) * | 2020-03-25 | 2025-04-18 | イーライ リリー アンド カンパニー | 多重特異性結合タンパク質およびそれを開発する方法 |
| BR112022023557A2 (pt) | 2020-05-20 | 2022-12-20 | Janssen Biotech Inc | Métodos para conjugação sítio-específica de proteínas contendo domínios fc glicosilados |
| AU2021350011A1 (en) * | 2020-09-25 | 2023-05-11 | Epivax, Inc. | Retro-inverso regulatory t cell epitopes |
| EP4392454A4 (en) * | 2021-08-27 | 2025-10-15 | Janssen Biotech Inc | ANTI-PSMA ANTIBODIES AND THEIR USES |
| CN117164701A (zh) * | 2022-12-27 | 2023-12-05 | 优洛生物(上海)有限公司 | 一种经改造的抗体、其制备方法及其用途 |
| EP4673474A2 (en) | 2023-02-28 | 2026-01-07 | Eisai R&D Management Co., Ltd. | Anti-psma antibodies, conjugates, and methods of use |
| US20240337664A1 (en) * | 2023-04-07 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Characterization of crosslinking sites in antibody-drug conjugates |
| CN119375471A (zh) * | 2023-07-26 | 2025-01-28 | 菲鹏生物股份有限公司 | 抗体和抗体缀合物及其用途 |
| WO2025199464A1 (en) | 2024-03-22 | 2025-09-25 | Eisai R&D Management Co., Ltd. | Anti-trop2 antibody-drug conjugates and methods of use |
| CN120779021A (zh) * | 2024-04-08 | 2025-10-14 | 菲鹏生物股份有限公司 | 抗体缀合物及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| CA2552043A1 (en) * | 2004-01-21 | 2005-08-04 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
| CA2813411C (en) * | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| WO2013176516A1 (ko) | 2012-05-24 | 2013-11-28 | 한화케미칼 주식회사 | 트랜스글루타미나아제를 이용하여 제조한 항체-약물 결합체 및 이의 용도 |
| EP2916872B1 (en) * | 2012-11-09 | 2019-02-27 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
| CN105517577A (zh) * | 2013-06-21 | 2016-04-20 | 先天制药公司 | 多肽的酶促偶联 |
| EP3019515B1 (en) * | 2013-07-11 | 2019-08-21 | Novartis AG | Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase |
| CA2919583C (en) * | 2013-07-31 | 2018-09-11 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates |
| CN106456798B (zh) | 2014-04-25 | 2021-02-12 | 瑞纳神经科学公司 | 具有高药物负载的抗体-药物缀合物 |
| RU2747581C2 (ru) * | 2015-12-18 | 2021-05-11 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Конъюгированные иммуноглобулины с c-концевым лизином |
| SG11201810470XA (en) | 2016-06-10 | 2018-12-28 | Eisai R&D Man Co Ltd | Lysine conjugated immunoglobulins |
-
2017
- 2017-06-12 SG SG11201810470XA patent/SG11201810470XA/en unknown
- 2017-06-12 WO PCT/JP2017/021672 patent/WO2017213267A1/en not_active Ceased
- 2017-06-12 CN CN201780043485.4A patent/CN109475642B/zh active Active
- 2017-06-12 RU RU2018145507A patent/RU2762939C2/ru active
- 2017-06-12 KR KR1020197000701A patent/KR102538866B1/ko active Active
- 2017-06-12 JP JP2018563925A patent/JP7041077B2/ja active Active
- 2017-06-12 BR BR112018075253-3A patent/BR112018075253A2/pt unknown
- 2017-06-12 RU RU2021136863A patent/RU2021136863A/ru unknown
- 2017-06-12 NZ NZ748605A patent/NZ748605A/en unknown
- 2017-06-12 MX MX2018015331A patent/MX419566B/es unknown
- 2017-06-12 EP EP17737890.8A patent/EP3468614A1/en active Pending
- 2017-06-12 AU AU2017279352A patent/AU2017279352B2/en active Active
- 2017-06-12 CA CA3026991A patent/CA3026991A1/en active Pending
- 2017-06-12 PE PE2018003193A patent/PE20190340A1/es unknown
- 2017-06-12 UA UAA201900242A patent/UA126799C2/uk unknown
- 2017-06-12 MY MYPI2018002415A patent/MY202858A/en unknown
- 2017-07-28 US US15/662,981 patent/US10941431B2/en active Active
-
2018
- 2018-11-27 IL IL263329A patent/IL263329B/en unknown
- 2018-12-07 CO CONC2018/0013314A patent/CO2018013314A2/es unknown
- 2018-12-09 JO JOP/2018/0118A patent/JOP20180118A1/ar unknown
- 2018-12-10 PH PH12018502594A patent/PH12018502594A1/en unknown
-
2021
- 2021-01-27 US US17/159,655 patent/US11753669B2/en active Active
- 2021-12-16 CL CL2021003383A patent/CL2021003383A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019525897A5 (cg-RX-API-DMAC7.html) | ||
| JP2019502684A5 (cg-RX-API-DMAC7.html) | ||
| JP7133611B2 (ja) | 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体 | |
| ES2277344T3 (es) | Purificacion de anticuerpos mediante cromatografia de interaccion hidrofobica a ph bajo. | |
| ES2549077T3 (es) | Espectrometría de masas de conjugados de anticuerpos | |
| JP2022023181A (ja) | Ｃ末端リジンで結合体化された免疫グロブリン | |
| JP6585600B2 (ja) | Ｃ末端軽鎖ポリペプチド伸長を含有する抗体、ならびにその複合体及びその使用方法 | |
| BR112015023589B1 (pt) | Método para a produção de um conjugado de imunoligante/carga útil | |
| JP7514836B2 (ja) | トランスグルタミナーゼによるコンジュゲーションのための改変抗体、ならびにそのコンジュゲート、方法および用途 | |
| CN109475642B (zh) | 赖氨酸缀合的免疫球蛋白 | |
| CN111712520A (zh) | 磷脂酰肌醇聚糖3抗体及其偶联物 | |
| JP2018520092A5 (cg-RX-API-DMAC7.html) | ||
| WO2012059882A2 (en) | Engineered polypeptide conjugates and methods for making thereof using transglutaminase | |
| JP7339291B2 (ja) | シクロホスファミド及びイホスファミドのイムノアッセイ用の免疫原及びアッセイ接合体として用いるシクロホスファミド類似体 | |
| US20220267467A1 (en) | Polypeptide complex for conjugation and use thereof | |
| CN110799537A (zh) | 抗pd-1抗体及其制备和使用方法 | |
| CN107029242A (zh) | 抗体药物复合物及其制造方法 | |
| CN108601848A (zh) | 用于制备细胞结合剂-细胞毒性剂缀合物的有效方法 | |
| CN117940459A (zh) | 靶向egfr和her3的双特异性四价抗体 | |
| AU2019386945B2 (en) | Antibody comprising a glutamine-containing light chain C-terminal extension, conjugates thereof, and methods and uses | |
| TWI591176B (zh) | 抗ｌｉｖ－１之人化抗體類及彼等於治療癌症上之用途 | |
| Benazza | New mass spectrometry (MS)-based approaches for the characterization of protein-drug-conjugates (PDCs) at intact and middle-levels | |
| CA3008645C (en) | C-terminal lysine conjugated immunoglobulins | |
| KR20250045545A (ko) | 항체-킬레이터 콘쥬게이트 | |
| BR112016018005B1 (pt) | Conjugados anticorpo-droga e imunotoxinas |